million
case
cancer
worldwid
approxim
tumor
associ
one
number
infecti
agent
virus
papillomaviru
hepat
b
c
virus
polyomavirus
bk
viru
jc
viru
merkel
cell
polyomaviru
mcpyv
epsteinbarr
viru
ebv
human
herpesviru
tcell
leukemia
viru
type
human
tcell
leukemia
viru
type
one
bacterium
helicobact
pylori
two
helminth
schistosom
liver
fluke
major
contributor
cancer
etiolog
agent
consid
thousand
microbi
speci
compris
normal
human
microbiom
like
microb
commun
substanti
influenc
normal
physiolog
well
caus
major
contributor
respons
diseas
includ
cancer
effect
subject
intens
investig
tissu
system
known
resid
microbiom
includ
gastrointestin
tract
skin
airway
immun
inflammatori
respons
microbiom
profil
also
examin
less
obviou
role
microb
presenc
unexpect
locat
exampl
relev
limit
cancer
includ
modul
tumor
microenviron
dysbiosi
bacteri
popul
breast
cancer
tissu
de
novo
catalogu
expand
count
microbi
speci
human
microbiom
character
distribut
metagenom
tool
need
effici
identifi
infecti
agent
strongli
associ
diseas
abil
evalu
contribut
microbiom
necessari
understand
interact
pathogen
pathogen
interact
commens
organ
host
genet
environment
factor
pcr
amplif
use
univers
rrna
primer
follow
amplicon
sequenc
wide
use
strategi
explor
investig
associ
microbiom
provid
effect
discoveri
tool
howev
work
bacteri
speci
amplicon
surviv
popul
pcr
virus
eukaryot
microorgan
rrna
sequenc
also
use
screen
larg
set
sampl
may
difficulti
discrimin
strain
report
presenc
genom
variant
pathogen
factor
deep
sequenc
total
dna
sampl
certainli
identifi
bacteri
viral
microbiom
member
sever
penalti
effici
even
field
attain
asyetunr
goal
cost
per
genom
total
dna
sequenc
expens
method
screen
hundr
thousand
experiment
control
sampl
detect
associ
pathogen
particular
diseas
depend
specimen
sampl
data
may
overwhelmingli
host
human
sequenc
creat
unnecessarili
larg
search
space
locat
pathogen
signatur
result
major
sequenc
read
discard
dna
microarray
use
metagenom
lawrenc
berkeley
labaffymetrix
phylochip
base
rrna
sequenc
academ
develop
virochip
probe
virus
success
detect
virus
patholog
sampl
virochip
platform
limit
virus
assay
rna
revers
transcrib
cdna
pcr
amplif
glomic
geochip
focus
rna
express
bacteria
human
microbiom
cover
bacteriophag
virus
eukaryot
microorgan
pathgen
dx
launch
pathchip
kit
featur
affymetrix
microarray
known
virus
broad
select
bacteria
eukaryot
pathogen
arraybas
tool
illustr
demand
method
quickli
econom
screen
set
sampl
broad
microbi
content
includ
speci
beyond
bacteria
report
describ
develop
pathochip
platform
contain
probe
known
publicli
avail
viru
sequenc
hundr
pathogen
bacteria
fungi
helminth
provid
wide
coverag
microbi
pathogen
econom
format
possibl
multipl
probe
independ
region
target
genom
use
improv
opportun
detect
furthermor
pathochip
content
develop
sequenc
known
target
abil
discov
new
strain
organ
provid
inclus
probe
sequenc
conserv
within
viral
famili
end
previous
unknown
viru
homolog
conserv
sequenc
may
produc
correspond
hybrid
signal
probe
complet
probe
set
support
workflow
describ
profil
larg
collect
tumor
sampl
typic
avail
formalinfix
paraffinembed
ffpe
tissu
biobank
includ
simultan
detect
dna
rna
expand
rang
target
avail
hybrid
pathochip
design
goal
cover
public
ncbi
viral
genom
genom
sequenc
broad
select
microorgan
bacteria
fungi
parasit
pathogen
human
use
multipl
probe
independ
target
site
genom
speci
fig
result
collect
pathogen
sequenc
assembl
metagenom
contain
chromosom
million
bp
access
virus
bacteria
fungi
parasit
agil
custom
probe
design
algorithm
built
compar
genom
hybrid
applic
use
identifi
million
probe
metagenom
million
probe
predict
low
risk
crosshybrid
human
genom
sequenc
importantli
subset
probe
map
uniqu
target
region
select
pathogen
synthes
pathochip
microarray
separ
subset
cover
region
sequenc
conserv
least
two
virus
synthes
pathochip
array
fig
enhanc
featur
pathochip
inclus
probe
tile
throughout
length
access
agent
known
tightli
associ
human
cancer
pilot
assay
use
agil
refer
human
dna
show
median
probe
intens
fluoresc
unit
probe
human
sequenc
around
fluoresc
unit
nonhuman
specif
probe
pathochip
fluoresc
unit
nonhuman
conserv
probe
pathochip
experi
tabl
assay
identifi
probe
fluoresc
valu
would
appar
abl
hybrid
human
dna
therefor
remov
consider
gener
pathochip
design
combin
uniqu
conserv
probe
set
fig
pilot
experi
indic
presenc
absenc
dna
made
differ
probe
perform
tabl
therefor
reagent
omit
subsequ
assay
interestingli
high
hybrid
intens
note
probe
epsteinbarr
viru
ebv
human
herpesviru
control
human
dna
manufactur
confirm
cell
line
use
prepar
male
femal
suretag
human
refer
dna
infect
viru
gener
cell
line
ebv
detect
tumor
screen
assay
use
reagent
therefor
possibl
signal
normal
ebv
probe
signal
xhh
channel
futur
assay
screen
util
virusfre
refer
human
dna
crosshybrid
control
valid
number
stringent
step
detect
known
virus
limit
amount
tissu
avail
tumor
archiv
obtain
clinic
procedur
fine
needl
aspir
biopsi
specimen
requir
metagenom
screen
protocol
includ
effici
strategi
nucleic
acid
extract
combin
amplif
step
allow
genom
transcriptomewid
represent
microbi
agent
present
sampl
method
must
addit
compat
degrad
dna
rna
typic
produc
formalin
tissu
fixat
draft
workflow
design
address
technic
hurdl
fig
pilot
experi
conduct
test
amplif
detect
number
positivecontrol
virus
three
wholegenom
amplif
wga
method
use
polymeras
rollingcircl
amplif
genomiphi
univers
primer
multiplex
pcr
genomeplex
transplex
singleprim
isotherm
amplif
ovat
wga
test
abil
detect
small
bacteriophag
genom
spike
background
human
dna
ng
dna
copi
number
rel
singlecopi
human
genom
locu
easili
detect
pathochip
probe
amplif
reaction
fig
test
detect
human
dna
rna
virus
dna
cell
line
contain
adenoviru
type
rna
contain
respiratori
syncyti
viru
amplifi
genomeplex
dna
transplex
rna
method
experi
tabl
cell
line
dna
rna
sampl
mix
simultan
amplifi
transplex
experi
tabl
probe
virus
produc
strong
specif
detect
signal
indic
transplex
revers
transcript
work
robustli
presenc
genom
dna
genom
dna
cdna
target
coamplifi
human
adenoviru
type
jc
polyomaviru
bk
polyomaviru
dna
ad
background
ng
human
dna
absolut
copi
number
rang
viral
genom
transplex
amplif
adenoviru
type
detect
pathochip
probe
copi
number
polyomaviru
probe
produc
detect
signal
background
detect
least
genom
copi
fig
genom
sequenc
human
cytomegaloviru
cmv
strain
laboratoryadapt
strain
differ
sever
locat
ncbi
refer
cmv
sequenc
clinic
strain
includ
larg
delet
dna
cell
line
infect
cmv
amplifi
hybrid
pathochip
includ
set
satur
tile
probe
cmv
refer
genom
probe
produc
high
signal
probe
locat
site
polymorph
delet
cmv
significantli
reduc
fluoresc
signal
clearli
delin
polymorph
delet
laboratori
strain
fig
allprep
dnarna
ffpe
kit
provid
effici
extract
genom
dna
total
rna
ffpe
specimen
kit
test
abil
importantli
extract
nucleic
acid
fungal
cell
gramneg
gramposit
bacteria
like
difficult
microbi
agent
sampl
dna
rna
saccharomyc
cerevisia
bacillu
cereu
escherichia
coli
cultur
effici
recov
use
kit
data
shown
provid
preliminari
indic
nucleic
acid
eukaryot
prokaryot
pathogen
extract
detect
pathochip
tumor
extract
procedur
fig
screen
perform
initi
set
eight
oropharyng
squamou
cell
carcinoma
oscc
head
neck
carcinoma
sampl
ffpe
tissu
specimen
human
overexpress
gene
correl
oncogen
human
papillomaviru
hpv
infect
oscc
immunohistochemistri
use
prognost
molecular
biomark
clinic
patholog
laboratori
high
sensit
poor
specif
hpv
oscc
sampl
includ
five
tumor
three
tumor
determin
patholog
hospit
univers
pennsylvania
pathochip
screen
four
five
tumor
produc
high
detect
signal
across
pathochip
probe
fifth
tumor
show
signal
small
subset
probe
remain
tumor
neg
pathochip
detect
fig
despit
good
hybrid
sampl
three
hpv
probe
tumor
two
probe
tumor
detect
signal
suggest
hpv
strain
variat
similar
result
polymorph
site
cmv
positivecontrol
experi
oncogen
virus
may
undergo
signific
genom
rearrang
delet
host
tumor
furthermor
viral
strain
wide
polymorph
detect
new
pathogen
may
reli
signal
singl
probe
sever
level
data
analysi
therefor
need
detect
three
main
class
hit
might
expect
screen
project
fig
access
signal
accsig
averag
probe
access
adjust
human
dna
crosshybrid
calcul
screen
detect
major
probe
access
set
mat
modelbas
analysi
tile
array
score
slide
window
probe
calcul
detect
local
area
high
signal
regardless
access
boundari
test
multipl
test
correct
employ
individu
probe
level
identifi
probe
signal
consist
higher
background
across
popul
tumor
outlier
analysi
conduct
probe
high
signal
one
tumor
screen
popul
data
screen
project
oscc
tumor
use
evalu
analysi
method
accsig
consist
patholog
report
fig
see
also
tabl
supplement
materi
tumor
produc
accsig
valu
eight
tumor
low
accsig
four
show
high
signal
subset
probe
produc
signific
accsig
valu
slide
window
analysi
recapitul
accsig
result
highlight
differ
detect
event
full
partial
genom
fig
metagenom
region
mat
score
compil
sampl
individu
probe
within
region
order
map
posit
plot
probe
signal
analysi
detect
number
organ
includ
pathogen
oral
bacteria
although
signal
lower
hpv
genom
preliminari
candid
investig
use
confirmatori
pcr
sequenc
method
analys
individu
probe
level
also
demonstr
util
identifi
candid
larg
major
probe
pass
test
signific
threshold
detect
signal
greater
background
across
tumor
popul
tabl
would
expect
genom
common
oscc
mani
probe
also
pass
outlier
test
indic
although
signal
consist
differ
background
popul
rang
intens
wide
therefor
also
contain
outlier
contrast
fewer
probe
signific
test
reflect
much
lower
appar
occurr
genom
tumor
popul
tabl
howev
outlier
analysi
easili
identifi
rel
larger
number
probe
produc
detect
accsig
mat
score
posit
sampl
rarer
candid
probe
signific
test
produc
lower
consist
signal
background
throughout
popul
may
account
copi
number
genom
present
surpris
also
illustr
need
examin
probelevel
hybrid
intens
analyz
algorithm
output
score
consid
candid
followup
valid
regardless
method
use
initi
identif
inspect
probe
intens
pathochip
screen
fig
reveal
pattern
high
low
signal
across
probe
set
tumor
sampl
high
low
undetect
signal
overal
pcr
primer
design
region
high
moder
signal
adjac
region
low
signal
primer
fig
pcr
genom
dna
repres
sampl
produc
appropri
amplicon
high
moderatesign
region
tumor
posit
detect
importantli
amplicon
observ
tumor
fig
occasion
faint
band
observ
amplicon
use
primer
expect
low
signal
probe
set
identifi
aliquot
transplex
product
use
pathochip
screen
combin
six
captur
pool
indic
fig
pool
mix
panel
biotinyl
dna
probe
includ
probe
pool
dna
hybrid
probe
captur
magnet
streptavidin
bead
deep
sequenc
librari
deriv
captur
materi
produc
number
read
map
high
homolog
genom
fig
read
enrich
region
target
captur
probe
also
includ
distal
sequenc
map
individu
read
librari
show
templat
present
sampl
pool
contain
tumor
neg
pathochip
assay
pool
fig
c
templat
pool
observ
librari
tumor
interestingli
region
high
read
show
high
intens
major
tumor
analyz
region
preval
major
tumor
fig
c
may
provid
window
transcript
profil
particular
type
oscc
oncogen
also
show
high
number
signal
tumor
dramat
surpris
open
read
frame
orf
region
howev
may
interest
discoveri
suggest
higher
number
transcript
orf
tumor
previous
thought
notabl
region
also
show
greater
signal
tile
probe
across
genom
predominantli
seem
promin
signal
oscc
tumor
suggest
greater
involv
mainten
tumor
hpv
previous
indic
abil
highli
multiplex
metagenom
assay
detect
small
nonhuman
genom
overwhelm
background
human
sequenc
affect
sever
factor
includ
nucleic
acid
extract
recoveri
target
size
copi
number
particip
amplif
reaction
use
specif
probe
perform
last
three
factor
like
contribut
differ
assay
perform
copi
jc
bk
polyomaviru
genom
doublestrand
circular
dna
plasmid
vector
detect
probe
intens
rang
jc
viru
probe
bk
viru
probe
contrast
adenoviru
type
genom
doublestrand
linear
nonintegr
dna
detect
intens
rang
use
probe
target
genom
copi
differ
genom
size
conform
may
affect
particip
wholegenom
amplif
reaction
furthermor
probe
clearli
differ
hybrid
affin
despit
share
bioinformat
design
criteria
pathochip
assay
sensit
therefor
vari
across
access
protocol
option
inclus
multipl
probe
per
access
integr
candid
differ
level
data
analysi
provid
avenu
optim
chanc
detect
pathogen
screen
project
genom
exampl
doublestrand
dna
dsdna
circl
detect
probe
intens
rang
natur
infect
tissu
specimen
oscc
integr
multipl
probe
analys
includ
accessionlevel
slide
window
individu
probe
comparison
detect
oscc
tumor
individu
test
pathochip
screen
occurr
rate
somewhat
higher
estim
rate
previous
report
unreason
given
rapidli
increas
preval
papillomavirus
oropharyng
cancer
result
assay
highli
concord
molecular
patholog
report
overexpress
case
suggest
hpv
strain
may
respons
detect
pathochip
assay
confirm
pcr
use
primer
independ
pathochip
probe
recoveri
sequenc
region
locat
outsid
target
captur
probe
hpv
genom
abil
pathochip
combin
satur
probe
set
rna
dna
detect
enhanc
screen
known
oncogen
pathogen
suffici
target
copi
present
sampl
infer
regard
genom
structur
variat
rna
express
level
may
possibl
probe
map
earli
gene
transcript
produc
overal
signal
late
gene
oscc
sampl
consist
studi
activ
infect
cell
oncogen
effect
express
moreov
transcript
hpv
level
detail
probe
greater
previous
investig
suggest
potenti
role
transcript
includ
orf
relat
antigen
mainten
transform
state
tumor
signal
probe
late
gene
sequenc
similar
somewhat
higher
probe
intergen
sequenc
therefor
boost
earli
gene
signal
like
due
rna
portion
sampl
target
prepar
among
earli
gene
strong
signal
observ
sequenc
region
known
highli
abund
rna
splice
product
primari
transcript
detail
interpret
data
complic
abil
exist
episom
multipl
hostgenom
integr
form
probe
signal
differ
within
tumor
provid
identif
potenti
agent
oncogen
activ
lead
new
line
investig
followup
initi
screen
experi
averag
probe
signal
access
provid
rapid
rather
uncompl
mean
summar
data
collect
strongest
detect
candid
slide
window
analysi
gener
match
accsig
result
provid
better
abil
distinguish
variant
within
set
sampl
offer
potenti
detect
candid
repres
portion
access
use
mat
algorithm
requir
labor
appli
sampl
separ
oper
could
address
futur
autom
script
analys
individu
probe
level
help
explain
candid
aros
accsig
mat
result
like
way
previous
unknown
pathogen
sequenc
homolog
conserv
specif
probe
detect
thu
pathochip
screen
project
gener
list
candid
priorit
magnitud
detect
detect
via
multipl
analysi
strategi
rate
detect
across
sampl
popul
combin
result
annot
viru
pathogen
microorgan
host
rang
tissu
specif
preval
gener
popul
assist
determin
agent
deserv
attent
approach
like
provid
signatur
particular
cancer
diseas
agent
variou
degre
contribut
window
natur
condit
commens
pathogen
organ
greatli
enhanc
abil
diagnos
treat
cancer
possibl
diseas
yet
link
specif
agent
pathochip
screen
assay
describ
support
faster
laboratori
data
analysi
turnaround
deep
sequenc
wholegenom
tumor
dna
rna
coverag
viral
eukaryot
genom
assay
rrna
approach
agil
sureprint
platform
rel
econom
compar
microarray
format
flexibl
quick
product
custom
probe
subset
updat
metagenom
compil
well
compat
varieti
upstream
sampl
prepar
strategi
pathochip
metagenom
assay
allow
comprehens
assess
frequenc
coinfect
multipl
organ
correl
drive
oncogen
event
event
lead
prolifer
earli
infect
process
well
extens
period
contribut
agent
may
vari
specif
effect
host
cell
import
diseas
develop
data
analysi
workflow
test
statist
signific
interact
infecti
agent
critic
studi
unfold
pathochip
data
combin
patient
genotyp
rna
profil
clinic
data
may
use
search
genet
environment
predisposit
influenc
hostpathogen
interact
import
initi
mainten
cancer
phenotyp
nation
center
biotechnolog
inform
ncbi
databas
genom
gene
nucleotid
access
queri
http
wwwncbinlmnihgovpubm
taxonomi
viru
annot
access
prokaryot
eukaryot
human
pathogen
list
compil
literatur
search
web
resourc
http
wwwniaidnihgov
emerg
reemerg
infecti
diseas
categori
b
c
prioriti
pathogen
result
access
assembl
nonredund
concaten
nucleotid
separ
access
metagenom
divid
chromosom
around
million
nucleotid
nt
length
submit
agil
technolog
santa
clara
ca
custom
design
project
probe
sequenc
maximum
nt
nonhybrid
spacer
select
use
agil
array
compar
genom
hybrid
acgh
design
algorithm
filter
low
likelihood
crosshybrid
human
genom
sequenc
independ
lowcomplex
region
metagenom
mask
use
mdust
http
docbioperlorgbioperlrunlibbiotoolsrunmdusthtml
follow
blastn
advanc
biocomput
llc
st
loui
mo
identif
uniqu
region
viral
access
criteria
uniqu
region
bp
contigu
bp
ident
sequenc
metagenom
access
conserv
viral
region
similarli
identifi
use
criteria
bp
ident
least
one
viru
human
sequenc
agilentdesign
probe
map
uniqu
conserv
region
pathogen
genom
prokaryot
eukaryot
pathogen
access
ad
microarray
design
default
fewer
probe
avail
sourc
access
otherwis
probe
filter
minimum
interprob
space
bp
distribut
roughli
cover
full
length
access
limit
number
probe
per
access
number
probe
restrict
known
oncogen
viral
agent
creat
satur
tile
set
cover
access
entir
genom
sequenc
cover
extent
possibl
avail
agilentdesign
probe
microarray
supplement
addit
number
predesign
acgh
probe
gene
intergen
region
human
genom
saccharomyc
cerevisia
probe
access
annot
avail
gene
express
omnibu
http
wwwncbinlmnihgovgeo
purifi
virion
dna
purchas
new
england
biolab
ipswich
usa
total
dna
human
cell
infect
cytomegaloviru
human
herpesviru
strain
atcc
total
dna
human
cell
infect
adenoviru
type
strain
adenoid
atcc
total
rna
human
cell
infect
respiratori
syncyti
viru
hrsv
strain
long
atcc
purchas
atcc
manassa
va
usa
plasmid
miniprep
prepar
subclon
carri
jc
bk
polyomaviru
genom
j
c
alwin
univers
pennsylvania
philadelphia
pa
carri
human
papillomaviru
genom
obtain
peter
howley
harvard
medic
school
boston
oropharyng
squamou
cell
carcinoma
tumor
sampl
obtain
abramson
cancer
center
tumor
tissu
biospecimen
bank
http
somappsmedupennedupbrportaltumor
sampl
review
resid
pathologist
case
histori
confirm
tumor
type
demarc
cancer
cell
signific
adjac
normal
tissu
present
section
mount
noncharg
glass
slide
dissect
tumor
tissu
use
templat
slide
hematoxylinandeosin
h
e
stain
section
cancer
region
clearli
demarc
specimen
contain
mostli
cancer
cell
provid
paraffin
roll
roll
mount
section
minimum
formalinfix
paraffinembed
ffpe
tumor
use
sequenti
dna
rna
extract
use
allprep
dnarna
ffpe
kit
qiagen
germantown
md
usa
nucleic
acid
qualiti
control
assess
includ
ratio
yield
size
distribut
agaros
gel
electrophoresi
trisbor
edta
buffer
system
expect
formalinexpos
rna
partial
degrad
howev
recoveri
sampl
rel
good
allow
process
sampl
fragment
size
accept
move
ahead
cdna
convers
wholegenom
amplif
wga
genom
dna
andor
cdna
randomprim
reversetranscrib
total
rna
perform
illustra
genomiphi
kit
ge
healthcar
bioscienc
pittsburgh
pa
usa
ovat
wga
system
nugen
san
carlo
ca
usa
genomeplex
transplex
kit
sigmaaldrich
st
loui
mo
use
manufacturerrecommend
protocol
input
amount
amplif
product
purifi
qiaquick
pcr
purif
kit
qiagen
use
dye
label
suretag
label
kit
agil
dye
label
perform
human
refer
dna
agil
suretag
kit
without
prior
wga
experi
tabl
wga
experi
control
report
probe
crosshybrid
human
dna
label
dna
purifi
suretag
kit
spin
column
specif
activ
calcul
use
hybrid
reaction
sureprint
glass
slide
microarray
agil
technolog
inc
manufactur
dna
oligom
synthes
featur
eight
replic
array
per
slide
pathochip
contain
probe
uniqu
target
region
conserv
plu
satur
target
region
respect
pathochip
contain
probe
uniqu
target
probe
conserv
target
satur
known
oncogen
pathogen
viral
agent
label
sampl
hybrid
microarray
describ
agil
oligonucleotid
arraybas
cgh
genom
dna
analysi
protocol
version
master
mix
contain
acgh
block
agent
hirpm
hybrid
buffer
dna
pilot
assay
ad
mixtur
entir
label
test
sampl
xhh
dna
control
sampl
denatur
hybrid
array
gasket
slide
rotat
h
agil
hybrid
oven
array
process
use
wash
procedur
scan
agil
surescan
microarray
scanner
scan
microarray
imag
analyz
use
agil
featur
extract
softwar
calcul
averag
pixel
intens
subtract
local
background
featur
imag
manual
examin
note
array
affect
high
background
scratch
technic
artifact
intens
distribut
channel
balanc
use
qualiti
control
expect
littl
signal
except
control
human
probe
featur
intens
channel
import
partek
genom
suit
partek
inc
st
loui
mo
usa
averag
intens
human
intergen
control
probe
calcul
cohybrid
test
xhh
dna
sampl
scale
factor
determin
would
make
xhh
dna
averag
equal
averag
intens
pathochip
probe
multipli
scale
factor
normal
differ
dye
perform
ratio
subtract
calcul
probe
provid
input
dualchannel
singlechannel
analysi
pipelin
respect
access
averag
accavg
defin
averag
intens
across
probe
one
access
access
signal
accsig
defin
accavg
accavg
modelbas
analysi
tile
array
mat
implement
partek
use
slide
window
analysi
probe
signal
minu
tumor
sampl
mat
paramet
p
valu
cutoff
window
bp
minimum
number
posit
probe
discard
valu
candid
region
classifi
mat
score
partek
analysi
varianc
anova
tool
use
perform
pair
test
multipl
test
correct
use
tumor
sampl
replic
test
condit
cohybrid
xhh
dna
replic
control
condit
comparison
perform
access
level
use
accavg
versu
accavg
individu
probe
level
use
versu
intens
valu
signific
threshold
set
stepup
fals
discoveri
rate
fold
differ
outlier
analysi
also
perform
access
probe
level
calcul
standard
deviat
accsig
probe
signal
across
tumor
filter
valu
standard
deviat
higher
popul
mean
pcr
amplif
reaction
mixtur
detect
contain
ng
tumor
dna
primer
aagcgaagacagcgggtatg
aggagtacctacgacatgggg
tggtgtttggcatatagtgtgtc
tggcgtgtctccatacactt
gtggtgggtgtagcttttcgt
tggcaagcaggaaacgtaca
dna
denatur
min
follow
cycl
magnet
bead
captur
use
creat
librari
target
sequenc
deep
sequenc
select
pathochip
probe
high
signal
candid
organ
synthes
dna
oligom
integr
dna
technolog
coralvil
ia
usa
mix
panel
includ
six
probe
fig
hybrid
pool
tumor
target
target
captur
pool
transplex
product
use
pathochip
screen
tumor
six
pool
ad
probe
panel
aliquot
contain
pmol
probe
ng
target
pool
reaction
mixtur
tmac
buffer
tetramethylammonium
chlorid
sarkosyl
mm
trishcl
mm
edta
ph
reaction
mixtur
denatur
min
follow
hybrid
h
streptavidin
dynabead
life
technolog
carlsbad
ca
usa
ad
continu
mix
room
temperatur
h
follow
three
wash
magnet
captur
beadprobetarget
complex
ml
ssc
ssc
nacl
plu
sodium
citrat
three
wash
ml
ssc
captur
singlestrand
target
dna
elut
trisedta
te
min
six
captur
eluat
reamplifi
genomeplex
reaction
sigmaaldrich
purifi
agencourt
ampur
xp
bead
beckman
coulter
indianapoli
usa
use
manufactur
protocol
assess
yield
qubit
doublestrand
dna
dsdna
assay
life
technolog
inc
size
distribut
agaros
gel
electrophoresi
sequenc
librari
prepar
use
nextera
xt
dna
sampl
prepar
kit
illumina
san
diego
ca
usa
dual
index
bead
librari
normal
accord
manufactur
protocol
qubit
quantit
librari
submit
washington
univers
genom
technolog
access
center
st
loui
mo
quantit
pcr
qpcr
qualiti
control
measur
librari
pool
sequenc
one
flow
cell
illumina
miseq
instrument
pairedend
read
approxim
read
six
oscc
librari
gener
align
pathochip
metagenom
human
genom
use
align
sensitiveloc
mode
read
map
mapq
score
better
identifi
use
integr
genom
viewer
research
describ
involv
anim
tumor
human
subject
collect
inform
consent
research
use
receiv
deidentifi
sampl
studi
approv
univers
pennsylvania
institut
review
board
